

### Company Overview

Emerald Bioscience is a biopharmaceutical company headquartered in Long Beach, California, focused on the discovery, development, and commercialization of bioengineered cannabinoid-based therapeutics for significant unmet medical needs in global markets. With proprietary technology licensed from the University of Mississippi, Emerald is developing novel ways to deliver cannabinoid-based drugs for specific indications with the aim of optimizing the clinical effects of such drugs while limiting potential adverse events. Emerald's strategy is to clinically develop a number of proprietary biosynthetic compounds, alone or in combination with corporate partners.

### Emerald Bioscience to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

Sep 3 2020, 11:39 AM EDT

### Emerald Bioscience Appoints Biotech Veteran Dr. Margaret Dalesandro to Board of Directors

Aug 13 2020, 8:30 AM EDT

### Emerald Bioscience Appoints Biotech Executive Punit Dhillon as CEO

Aug 10 2020, 8:30 AM EDT

### Stock Overview

Symbol	EMBI
Exchange	OTCQB
Market Cap	8.86m
Last Price	\$0.03
52-Week Range	\$0.03 - \$0.49

09/25/2020 03:51 PM EDT

### Investor Relations

EMBI Investor Relations  
T: 949-396-0330  
[invest@emeraldbio.life](mailto:invest@emeraldbio.life)

### Management Team

#### Punit Dhillon

Chief Executive Officer and Executive Chairman

#### Dennis Kim, MD, MBA

Chief Medical Officer

#### Alice Chen

Executive Director, Clinical Operations

#### Elena Traistaru

Primary Financial and Accounting Officer, Secretary

### Emerald Bioscience, Inc.

130 North Marina Drive  
Long Beach, CA 90803

### Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.